S&P Dow Jones Indices said the addition is effective Jan. 14, when medical technology company Enovis will move from the S&P MidCap 400 to the S&P SmallCap 600. Enovis is replacing Arch Resources, ...
Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE: ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE: ARCH) in the S&P SmallCap 600 effective prior to the ...
Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic ...
Maplebear had a net margin of 13.37% and a return on equity of 13.78%. The firm had revenue of $852.00 million for the quarter, compared to analysts’ expectations of $844.03 million.
Some results have been hidden because they may be inaccessible to you